JP2002511741A - 細胞のｄｎａに核酸を導入するためのｄｎａ系トランスポゾンシステム - Google Patents

細胞のｄｎａに核酸を導入するためのｄｎａ系トランスポゾンシステム

Info

Publication number
JP2002511741A
JP2002511741A JP53972098A JP53972098A JP2002511741A JP 2002511741 A JP2002511741 A JP 2002511741A JP 53972098 A JP53972098 A JP 53972098A JP 53972098 A JP53972098 A JP 53972098A JP 2002511741 A JP2002511741 A JP 2002511741A
Authority
JP
Japan
Prior art keywords
nucleic acid
protein
cell
dna
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP53972098A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002511741A5 (https=
Inventor
ビー． ハケット，ペリー
イフィックス，ツォルタン
イツファック，ツザンナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota Twin Cities
Original Assignee
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota System filed Critical University of Minnesota System
Publication of JP2002511741A publication Critical patent/JP2002511741A/ja
Publication of JP2002511741A5 publication Critical patent/JP2002511741A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP53972098A 1997-03-11 1998-03-11 細胞のｄｎａに核酸を導入するためのｄｎａ系トランスポゾンシステム Withdrawn JP2002511741A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US4066497P 1997-03-11 1997-03-11
US60/040,664 1997-03-11
US5386897P 1997-07-28 1997-07-28
US60/053,868 1997-07-28
US6530397P 1997-11-13 1997-11-13
US60/065,303 1997-11-13
PCT/US1998/004687 WO1998040510A1 (en) 1997-03-11 1998-03-11 Dna-based transposon system for the introduction of nucleic acid into dna of a cell

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008140004A Division JP2008271981A (ja) 1997-03-11 2008-05-28 細胞のｄｎａに核酸を導入するためのｄｎａ系トランスポゾンシステム

Publications (2)

Publication Number Publication Date
JP2002511741A true JP2002511741A (ja) 2002-04-16
JP2002511741A5 JP2002511741A5 (https=) 2005-11-10

Family

ID=27365765

Family Applications (2)

Application Number Title Priority Date Filing Date
JP53972098A Withdrawn JP2002511741A (ja) 1997-03-11 1998-03-11 細胞のｄｎａに核酸を導入するためのｄｎａ系トランスポゾンシステム
JP2008140004A Pending JP2008271981A (ja) 1997-03-11 2008-05-28 細胞のｄｎａに核酸を導入するためのｄｎａ系トランスポゾンシステム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008140004A Pending JP2008271981A (ja) 1997-03-11 2008-05-28 細胞のｄｎａに核酸を導入するためのｄｎａ系トランスポゾンシステム

Country Status (10)

Country Link
US (2) US6489458B2 (https=)
EP (1) EP0973928B1 (https=)
JP (2) JP2002511741A (https=)
KR (1) KR20000076157A (https=)
AT (1) ATE466948T1 (https=)
AU (1) AU745049B2 (https=)
CA (1) CA2280997C (https=)
DE (1) DE69841648D1 (https=)
DK (1) DK0973928T3 (https=)
WO (1) WO1998040510A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008271981A (ja) * 1997-03-11 2008-11-13 Regents Of The Univ Of Minnesota 細胞のｄｎａに核酸を導入するためのｄｎａ系トランスポゾンシステム
JP2022093564A (ja) * 2014-04-23 2022-06-23 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法

Families Citing this family (238)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1034258A2 (en) * 1997-11-13 2000-09-13 The Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the dna of a cell
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
EP1155131B1 (en) * 1999-02-19 2008-07-23 ABT Holding Company Vector comprising a splice acceptor trap and a poly a trap and the corresponding eukaryotic host cells
US6299850B1 (en) 1999-03-16 2001-10-09 The United States Of America As Represented By The Department Of Energy Carbon activation process for increased surface accessibility in electrochemical capacitors
US6562624B2 (en) 1999-03-17 2003-05-13 Paradigm Genetics, Inc. Methods and materials for the rapid and high volume production of a gene knock-out library in an organism
JP2002543792A (ja) * 1999-05-11 2002-12-24 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ベクターによるトランスポゾン配列の供給及び組込み
US7196244B1 (en) * 1999-06-01 2007-03-27 University Of Utah Method of transposon-mediated mutagenesis in the nematode caenorhabditis elegans
WO2001029205A2 (en) * 1999-10-19 2001-04-26 Minos Biosystems Limited Method for genetic manipulation
AU7900300A (en) * 1999-10-26 2001-05-08 Shanghai Bio Road Gene Development Ltd. A novel polypeptide - human pogo transposase 14 and a polynucleotide encoding the same
AU1100201A (en) * 1999-10-28 2001-05-08 Board Of Trustees Of The Leland Stanford Junior University Methods of in vivo gene transfer using a sleeping beauty transposon system
CN1300827A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽—人水手转座酶19和编码这种多肽的多核苷酸
JP2001231567A (ja) * 2000-02-18 2001-08-28 Inst Of Physical & Chemical Res テロメア長の調節方法
JP4751556B2 (ja) * 2000-02-28 2011-08-17 ジーンシーグス， インコーポレイテッド ナノカプセルカプセル化システムおよび方法
CA2407651C (en) * 2000-04-27 2013-07-02 Max-Delbruck-Centrum Fur Molekulare Medizin Sleeping beauty, a transposon vector with a broad host range for the genetic transformation in vertebrates
WO2002086074A2 (en) * 2001-04-20 2002-10-31 Regents Of The University Of Minnesota Compositions for delivery of compounds to cells and methods of use
EP1308516A1 (en) * 2001-10-24 2003-05-07 ADEREGEM (Association pour le Développement de la Recherche en Génétique Moléculaire Site-directed recombinase fusion proteins and corresponding polynucleotides, vectors and kits, and their uses for site-directed DNA recombination
AU2003231048A1 (en) * 2002-04-22 2003-11-03 Regents Of The University Of Minnesota Transposon system and methods of use
US7164056B2 (en) 2002-05-03 2007-01-16 Pioneer Hi-Bred International, Inc. Gene targeting using replicating DNA molecules
DE10224242A1 (de) * 2002-05-29 2003-12-11 Max Delbrueck Centrum Frog Prince, ein Transposonvektor für den Gentransfer bei Wirbeltieren
US20040172667A1 (en) * 2002-06-26 2004-09-02 Cooper Richard K. Administration of transposon-based vectors to reproductive organs
US7527966B2 (en) * 2002-06-26 2009-05-05 Transgenrx, Inc. Gene regulation in transgenic animals using a transposon-based vector
EP1380289A1 (en) * 2002-07-10 2004-01-14 Denis Bron Delivery system for pharmaceutical agents
TW200411052A (en) * 2002-07-12 2004-07-01 Takara Bio Inc Method of transferring mutation into target nucleic acid
DK1594973T3 (da) 2003-02-10 2012-02-13 Max Delbrueck Centrum Transposonbaseret målretningssystem
ATE498016T1 (de) * 2003-02-10 2011-02-15 Max Delbrueck Centrum Transposon-system zur gezielten integration
DK1594971T3 (da) * 2003-02-10 2011-05-23 Max Delbrueck Centrum Transposonbaseret målretningssystem
US7985739B2 (en) 2003-06-04 2011-07-26 The Board Of Trustees Of The Leland Stanford Junior University Enhanced sleeping beauty transposon system and methods for using the same
WO2005003359A1 (ja) * 2003-07-08 2005-01-13 Japan Science And Technology Corporation トランスジェニック生物を作製する方法およびシステム
US7194978B2 (en) * 2003-08-22 2007-03-27 University Of Maryland Biotechnology Institute Inducing sterility in fish by disrupting the development of the GnRH system
WO2005062881A2 (en) * 2003-12-24 2005-07-14 Transgenrx, Inc. Gene therapy using transposon-based vectors
US7727744B2 (en) 2004-03-30 2010-06-01 Epicentre Technologies Corporation Methods for obtaining directionally truncated polypeptides
US20060294606A1 (en) * 2004-05-18 2006-12-28 Istefo Moisyadi Tn5 transposase-mediated transgenesis
US20060026699A1 (en) * 2004-06-04 2006-02-02 Largaespada David A Methods and compositions for identification of genomic sequences
NZ554824A (en) 2004-10-22 2010-10-29 Revivicor Inc Porcines that lack endogenous antibody chains and express exogenous immunoglobulins
US7919583B2 (en) * 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
EP2160461B1 (en) 2007-07-04 2012-08-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Hyperactive variants of the transposase protein of the transposon system sleeping beauty
DE102007048134A1 (de) * 2007-10-05 2009-04-09 Evocatal Gmbh Verfahren und Gen-Kassetten zur Klonierung, Integration und Expression mehrerer Gene eines Genclusters
CA2621155A1 (en) * 2008-02-29 2009-08-29 James Ellis Stem cell expression cassettes
WO2010008564A2 (en) * 2008-07-16 2010-01-21 Recombinetics Plaice dna transposon system
WO2010036976A2 (en) * 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of antibodies
US9157097B2 (en) * 2008-09-25 2015-10-13 Proteovec Holding, L.L.C. Vectors for production of growth hormone
WO2010036979A2 (en) * 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of interferon
EP2348827B1 (en) 2008-10-27 2015-07-01 Revivicor, Inc. Immunocompromised ungulates
AU2010206374B2 (en) 2009-01-23 2013-01-17 Gloriana Therapeutics Sarl Improved cell lines and their use in encapsulated cell biodelivery
EP2389191A2 (en) 2009-01-23 2011-11-30 NsGene A/S Expression of neuropeptides in mammalian cells
EP2417263B1 (en) * 2009-04-09 2015-09-23 ProteoVec Holding L.L.C. Production of proteins using transposon-based vectors
WO2010124200A2 (en) * 2009-04-23 2010-10-28 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for cancer
EP2449112A1 (en) 2009-07-01 2012-05-09 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for severe combined immunodeficiency (scid)
US8502015B1 (en) 2009-07-06 2013-08-06 Transgenex Nanobiotech, Inc. Method of inducing cancer
EP2454368A4 (en) 2009-07-17 2013-01-09 Aaron Thomas Tabor COMPOSITIONS AND METHOD FOR THE GENETIC MODIFICATION OF COSMETIC FUNCTION CELLS FOR IMPROVING THE COSMETIC APPEARANCE PICTURE
WO2011011678A2 (en) 2009-07-24 2011-01-27 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for cytokine-cytokine signaling pathways
EP2460016A2 (en) * 2009-07-30 2012-06-06 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for pharmacokinetics
EP2462230B1 (en) * 2009-08-03 2015-07-15 Recombinetics, Inc. Methods and compositions for targeted gene modification
WO2011017518A2 (en) 2009-08-05 2011-02-10 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for drug metabolism
EP2467013A2 (en) 2009-08-20 2012-06-27 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for pain
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
WO2011153440A2 (en) 2010-06-04 2011-12-08 Regents Of The University Of Minnesota Transposon mutagenesis system and methods of use
RU2447150C1 (ru) * 2010-11-26 2012-04-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН Средство для генной терапии злокачественных опухолей
WO2012129198A1 (en) 2011-03-23 2012-09-27 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for obesity and diabetes
ES2528892T3 (es) 2012-07-30 2015-02-13 Nbe-Therapeutics Llc Identificación mediada por trasposición de proteínas de unión o funcionales específicas
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
AU2014268364A1 (en) 2013-05-24 2015-12-10 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
EP3656864A1 (en) 2014-02-14 2020-05-27 Board of Regents, The University of Texas System Chimeric antigen receptors and methods of making
CA2959660A1 (en) 2014-09-03 2016-03-10 Genesegues, Inc. Therapeutic nanoparticles and related compositions, methods, and systems
AU2015343013B2 (en) 2014-11-05 2020-07-16 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
CA2964783C (en) 2014-11-05 2024-01-23 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
WO2021173560A1 (en) 2020-02-24 2021-09-02 Immatics US, Inc. Methods for expanding t cells for the treatment of cancer and related malignancies
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
KR102615825B1 (ko) 2015-03-11 2023-12-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 전위효소 폴리펩타이드 및 이의 용도
TW202523682A (zh) 2015-05-20 2025-06-16 美商博德研究所有限公司 共有之gata3相關之腫瘤特異性新抗原
CA3012607A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Crispr enzymes and systems
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
US11059879B2 (en) 2015-10-27 2021-07-13 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
AU2016355178B9 (en) 2015-11-19 2019-05-30 Massachusetts Institute Of Technology Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
GB201602473D0 (en) 2016-02-11 2016-03-30 Horizon Discovery Ltd Replicative transposon system
EP3219803A1 (en) 2016-03-15 2017-09-20 Max-Delbrück-Centrum für Molekulare Medizin Enhanced sleeping beauty transposons, kits and methods of transposition
WO2020047527A2 (en) 2018-09-02 2020-03-05 F1 Bioventures, Llc Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
SG10202012157QA (en) 2016-06-07 2021-01-28 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Chimeric antigen receptor and car-t cells that bind bcma
SG11201810640RA (en) 2016-06-08 2018-12-28 Intrexon Corp Cd33 specific chimeric antigen receptors
US11630103B2 (en) 2016-08-17 2023-04-18 The Broad Institute, Inc. Product and methods useful for modulating and evaluating immune responses
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
WO2018064208A1 (en) 2016-09-28 2018-04-05 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2018089386A1 (en) 2016-11-11 2018-05-17 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
KR20190102259A (ko) 2017-01-10 2019-09-03 인트렉손 코포레이션 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2018148671A1 (en) 2017-02-12 2018-08-16 Neon Therapeutics, Inc. Hla-based methods and compositions and uses thereof
AU2018226884B2 (en) 2017-03-03 2024-11-07 Exuma Biotech, Corp. Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
EP3606518A4 (en) 2017-04-01 2021-04-07 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
WO2018191558A1 (en) 2017-04-12 2018-10-18 The Broad Institute, Inc. Modulation of epithelial cell differentiation, maintenance and/or function through t cell action, and markers and methods of use thereof
US20200071773A1 (en) 2017-04-12 2020-03-05 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
US20210293783A1 (en) 2017-04-18 2021-09-23 The General Hospital Corporation Compositions for detecting secretion and methods of use
EP3622092A4 (en) 2017-05-11 2021-06-23 The Broad Institute, Inc. METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
EP3625342B1 (en) 2017-05-18 2022-08-24 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
EP3635132A4 (en) 2017-06-07 2021-05-26 Intrexon Corporation EXPRESSION OF NOVEL CELL MARKERS
WO2018232195A1 (en) 2017-06-14 2018-12-20 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
BR112020001719A2 (pt) 2017-07-29 2020-07-21 Juno Therapeutics Inc reagentes para expansão de células que expressam receptores recombinantes
SG11202001011XA (en) 2017-08-23 2020-03-30 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Chimeric antigen receptor and car-t cells that bind cxcr5
JP2020535802A (ja) 2017-09-21 2020-12-10 ザ・ブロード・インスティテュート・インコーポレイテッド 標的化核酸編集のための系、方法、及び組成物
EP3695408B1 (en) 2017-10-02 2026-01-21 The Broad Institute, Inc. Medical use of cdk4/6- and checkpoint-inhibitors in phased combination, in treatment of cancer
WO2019084055A1 (en) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
SG11202003657VA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Process for producing a t cell composition
EP3704230B1 (en) 2017-11-01 2024-10-23 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
WO2019094955A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
EP4501408A3 (en) 2017-11-17 2025-04-09 Iovance Biotherapeutics, Inc. Til expansion from fine needle aspirates and small biopsies
EP3714041A1 (en) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
WO2019113557A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
SG11202006541UA (en) 2018-01-08 2020-08-28 Iovance Biotherapeutics Inc Processes for generating til products enriched for tumor antigen-specific t-cells
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
WO2019173465A1 (en) 2018-03-06 2019-09-12 Intrexon Corporation Human papillomavirus vaccines and uses of the same
SG11202009626QA (en) 2018-04-20 2020-10-29 Medizinische Hochschule Hannover Chimeric antigen receptor and car-t cells that bind a herpes virus antigen
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
US20210130779A1 (en) 2018-04-27 2021-05-06 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
US12391685B2 (en) 2018-08-20 2025-08-19 The Broad Institute, Inc. Inhibitors of RNA-guided nuclease target binding and uses thereof
US12460244B2 (en) 2018-08-20 2025-11-04 The Broad Institute, Inc. Inhibitors of RNA-guided nuclease activity and uses thereof
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
US20220170097A1 (en) 2018-10-29 2022-06-02 The Broad Institute, Inc. Car t cell transcriptional atlas
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
TW202039830A (zh) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途
TW202039831A (zh) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 對抗ｐｄ－１抗體呈現難治性之非小細胞肺癌（ｎｓｃｌｃ）病患之治療
US20230039976A1 (en) 2018-11-05 2023-02-09 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
JP7710372B2 (ja) 2018-12-19 2025-07-18 アイオバンス バイオセラピューティクス，インコーポレイテッド 操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用
AU2019404547B2 (en) 2018-12-21 2025-01-30 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
US20220133795A1 (en) 2019-03-01 2022-05-05 Iovance Biotherapeutics, Inc. Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
US20220142948A1 (en) 2019-03-18 2022-05-12 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
JP2022526340A (ja) 2019-03-25 2022-05-24 マックス－デルブリュック－ツェントルム フューア モレキュラーレ メディツィン イン デア ヘルムホルツ－ゲマインシャフト Ｅｂａｇ９を阻害することによる細胞溶解性ｔ細胞の活性の増強
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
US20220226464A1 (en) 2019-05-28 2022-07-21 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
US20220298221A1 (en) 2019-06-05 2022-09-22 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Chimeric autoantibody receptor (caar) that binds autoantibodies targeting the central nervous system in neurological autoimmune disease
JP2022539248A (ja) 2019-07-02 2022-09-07 フレッド ハッチンソン キャンサー リサーチ センター 組換えａｄ３５ベクター及び関連遺伝子治療改善
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
JP2022553389A (ja) 2019-10-25 2022-12-22 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
US20220412954A1 (en) 2019-11-05 2022-12-29 Juno Therapeutics, Inc. Methods of determining attributes of therapeutic t cell compositions
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
US12516291B2 (en) 2019-12-11 2026-01-06 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
CN113584083A (zh) 2020-04-30 2021-11-02 深圳市深研生物科技有限公司 用于逆转录病毒载体的生产细胞和包装细胞及其制备方法
EP4146794A1 (en) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
TW202208616A (zh) 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 改良之腫瘤反應性ｔ細胞的選擇
JP7727662B2 (ja) 2020-05-13 2025-08-21 ジュノー セラピューティクス インコーポレイテッド 臨床応答に関連する特徴量の特定方法およびその使用
WO2021260696A1 (en) 2020-06-22 2021-12-30 Ramot At Tel-Aviv University Ltd. Multi subunit protein modules, cells expressing same and uses thereof
EP4199959A1 (en) 2020-08-24 2023-06-28 Charité - Universitätsmedizin Berlin A chimeric antigen receptor construct encoding a checkpoint inhibitory molecule and an immune stimulatory cytokine and car-expressing cells recognizing cd44v6
JP7849891B2 (ja) 2020-08-24 2026-04-22 シャリテ－ウニベルジテーツメディツィン ベルリン Ｃｅａを認識するキメラ抗原受容体（ｃａｒ）発現細胞
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
TW202241468A (zh) 2020-12-11 2022-11-01 美商艾歐凡斯生物治療公司 用腫瘤浸潤性淋巴球療法與ｂｒａｆ抑制劑及／或ｍｅｋ抑制劑組合治療癌症患者
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
CA3202483A1 (en) 2020-12-17 2022-06-23 Maria Fardis Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
WO2022136503A1 (en) 2020-12-22 2022-06-30 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Chimeric autoantibody receptor (caar) comprising a nicotinic acetylcholine receptor autoantigen
EP4019538A1 (en) 2020-12-22 2022-06-29 Charité - Universitätsmedizin Berlin Reprogramming immune cells by targeted integration of zeta-deficient chimeric antigen receptor transgenes
EP4271817A2 (en) 2020-12-30 2023-11-08 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
WO2022155500A1 (en) 2021-01-14 2022-07-21 Senti Biosciences, Inc. Secretable payload regulation
TW202241508A (zh) 2021-01-29 2022-11-01 美商艾歐凡斯生物治療公司 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
WO2022187289A1 (en) 2021-03-01 2022-09-09 Exuma Biotech Corp. Methods and compositions for the delivery of retroviral particles
WO2022198141A1 (en) 2021-03-19 2022-09-22 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
KR20230159851A (ko) 2021-03-22 2023-11-22 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 결정하는 방법
AU2022246174A1 (en) 2021-03-25 2023-09-14 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
EP4326287A2 (en) 2021-04-19 2024-02-28 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2022245754A1 (en) 2021-05-17 2022-11-24 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
US20240365776A1 (en) 2021-07-22 2024-11-07 Iovance Biotherapeutics, Inc Method for cryopreservation of solid tumor fragments
US20240342285A1 (en) 2021-07-28 2024-10-17 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
IL311333A (en) 2021-09-09 2024-05-01 Iovance Biotherapeutics Inc Processes for generating til products using pd-1 talen knockdown
WO2023077015A2 (en) 2021-10-27 2023-05-04 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
EP4430167A1 (en) 2021-11-10 2024-09-18 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
GB202117314D0 (en) 2021-11-30 2022-01-12 Clarke David John Cyclic nucleic acid fragmentation
US20250051735A1 (en) 2021-12-22 2025-02-13 Vanderbilt University Next generation transpososomes
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
WO2023150181A1 (en) 2022-02-01 2023-08-10 President And Fellows Of Harvard College Methods and compositions for treating cancer
EP4476331A2 (en) 2022-02-07 2024-12-18 Ensoma, Inc. Inhibitor-resistant mgmt modifications and modification of mgmt-encoding nucleic acids
US20250099612A1 (en) 2022-03-01 2025-03-27 Exuma Biotech Corp. Viral particles with membrane-bound hyaluronidase
WO2023173137A1 (en) 2022-03-11 2023-09-14 Yale University Compositions and methods for efficient and stable genetic modification of eukaryotic cells
WO2023183344A1 (en) 2022-03-21 2023-09-28 Alaunos Therapeutics, Inc. Methods for identifying neoantigen-reactive t cell receptors
EP4504220A1 (en) 2022-04-06 2025-02-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
CA3248034A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
EP4522202A1 (en) 2022-05-10 2025-03-19 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
CA3253031A1 (en) 2022-05-27 2023-11-30 Kite Pharma, Inc. NON-VIRAL ADMINISTRATION OF CELL THERAPY CONSTRUCTIONS
EP4565683A1 (en) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
CN116949092A (zh) * 2022-09-21 2023-10-27 上海吉量医药工程有限公司 一种转座子系统及其应用
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
EP4353253A1 (en) 2022-10-10 2024-04-17 Charité - Universitätsmedizin Berlin Purification of tcr-modified t cells using tcr-specific car-nk cells
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2024098027A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
CN120548323A (zh) 2022-11-18 2025-08-26 首尔国立大学校产学协力团 利用ctla-4变体及嵌合抗原受体的双基因转导免疫细胞及其用途
WO2024112711A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Methods for assessing proliferation potency of gene-edited t cells
EP4623072A2 (en) 2022-11-21 2025-10-01 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024154122A1 (en) 2023-01-18 2024-07-25 Gilboa Therapeutics LTD Immune cells expressing a complement receptor and uses thereof
WO2024197072A2 (en) 2023-03-21 2024-09-26 Alaunos Therapeutics, Inc. Identification of neoantigen-reactive t cell receptors
KR20250169631A (ko) 2023-04-18 2025-12-03 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
CN121464348A (zh) 2023-05-23 2026-02-03 朱诺治疗学股份有限公司 T细胞的激活标记物和评估t细胞激活的方法
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025096916A1 (en) 2023-11-03 2025-05-08 The Broad Institute, Inc. Multi-site editing in living cells
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
WO2025120230A1 (en) 2023-12-07 2025-06-12 T-Curx Gmbh Method of producing leukocytes expressing artificial antigen receptors
WO2025158420A1 (en) 2024-01-25 2025-07-31 Nanocell Therapeutics Holdings B.V. Methods and composition for inducing activation and dna expression in t-cells
WO2025169168A1 (en) 2024-02-09 2025-08-14 Nanocell Therapeutics Holdings B.V. Extracorporeal transfection of immune effector cells
WO2025176860A1 (en) 2024-02-23 2025-08-28 Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts Dual chimeric antigen receptor construct targeting cea and epcam
WO2026050217A2 (en) 2024-08-27 2026-03-05 Iovance Biotherapeutics, Inc. Engineered artificial antigen presenting cells and lipid nanoparticles for tumor infiltrating lymphocyte expansion
WO2026073244A1 (en) 2024-09-30 2026-04-02 Ensoma, Inc. Constructs for multi-lineage expression of therapeutic agents

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631259A (en) 1983-05-04 1986-12-23 Board Of Regents Of The University Of Michigan Transposon in cloning DNA
WO1988001646A1 (en) 1986-08-26 1988-03-10 Allelix Inc. Universal system for transposon mutagenesis
FR2627508B1 (fr) 1988-02-22 1990-10-05 Eurolysine Procede pour l'integration d'un gene choisi sur le chromosome d'une bacterie et bacterie obtenue par ledit procede
EP0485701A1 (en) 1990-09-28 1992-05-20 American Cyanamid Company Insertion of DNA by modified transposons
ES2121794T3 (es) 1990-10-25 1998-12-16 Clague Pitman Hodgson Procedimiento de transferencia de genes por medio de retrotransposones.
WO1993004701A1 (en) 1991-09-05 1993-03-18 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
WO1993025239A1 (en) 1992-06-17 1993-12-23 Advanced Magnetics Inc. Arabinogalactan derivatives and uses thereof
US6225121B1 (en) 1992-09-14 2001-05-01 Institute Of Molecular Biology And Biotechnology/Forth Eukaryotic transposable element
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5589362A (en) 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
WO1995001095A1 (en) 1993-06-30 1995-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Transformed eukaryotic cells, and transposon-based transformation vectors
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
CA2180202A1 (en) 1995-06-30 1996-12-31 Mika Moriya Method of amplifying gene using artificial transposon
WO1997015679A1 (en) 1995-10-27 1997-05-01 The Trustees Of The University Of Pennsylvania Recombinant viruses containing mobile genetic elements and methods of use in gene therapy
JP2001503962A (ja) 1996-02-09 2001-03-27 ヘット ネーデルランツ カンケル インスティチュート 細胞のゲノム中に組込まれる付加核酸物質を細胞に付与するためのベクターおよび方法
US5948681A (en) 1996-08-14 1999-09-07 Children's Hospital Of Philadelphia Non-viral vehicles for use in gene transfer
US5928888A (en) 1996-09-26 1999-07-27 Aurora Biosciences Corporation Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities
AU5588298A (en) 1996-12-02 1998-06-29 Cell Genesys, Inc. Adeno-associated viral vector-mediated delivery of dna to cells of the liver
US6489458B2 (en) 1997-03-11 2002-12-03 Regents Of The University Of Minnesota DNA-based transposon system for the introduction of nucleic acid into DNA of a cell
WO1998056903A1 (en) 1997-06-13 1998-12-17 President And Fellows Of Harvard College Methods and uses for transposon-based gene targeting
EP1034258A2 (en) 1997-11-13 2000-09-13 The Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the dna of a cell
MXPA00011312A (es) 1998-05-20 2003-04-22 Expression Genetics Inc Un vehiculo de gen polimerico de poli-l.lisina injertada con polietilenglicol con porcion de enfoque hepatocitos.
US6303362B1 (en) 1998-11-19 2001-10-16 The Board Of Trustees Of The Leland Stanford Junior University Adenoviral vector and methods for making and using the same
JP2002543792A (ja) 1999-05-11 2002-12-24 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ベクターによるトランスポゾン配列の供給及び組込み
AU1100201A (en) 1999-10-28 2001-05-08 Board Of Trustees Of The Leland Stanford Junior University Methods of in vivo gene transfer using a sleeping beauty transposon system
CA2407651C (en) 2000-04-27 2013-07-02 Max-Delbruck-Centrum Fur Molekulare Medizin Sleeping beauty, a transposon vector with a broad host range for the genetic transformation in vertebrates
US20020115216A1 (en) 2000-05-19 2002-08-22 Steer Clifford J. Composition for delivery of compounds to cells
AU2001265187A1 (en) 2000-05-30 2001-12-11 Baylor College Of Medicine Chimeric viral vectors for gene therapy
JP2004267001A (ja) 2000-08-16 2004-09-30 Kansai Tlo Kk トランスジェニック哺乳動物及びその作製方法並びにこれを用いた遺伝子機能の解明方法
US7985739B2 (en) 2003-06-04 2011-07-26 The Board Of Trustees Of The Leland Stanford Junior University Enhanced sleeping beauty transposon system and methods for using the same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008271981A (ja) * 1997-03-11 2008-11-13 Regents Of The Univ Of Minnesota 細胞のｄｎａに核酸を導入するためのｄｎａ系トランスポゾンシステム
JP2022093564A (ja) * 2014-04-23 2022-06-23 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法

Also Published As

Publication number Publication date
US20030124668A1 (en) 2003-07-03
CA2280997C (en) 2013-05-28
EP0973928A1 (en) 2000-01-26
WO1998040510A1 (en) 1998-09-17
JP2008271981A (ja) 2008-11-13
AU6456998A (en) 1998-09-29
DE69841648D1 (de) 2010-06-17
ATE466948T1 (de) 2010-05-15
KR20000076157A (ko) 2000-12-26
US7148203B2 (en) 2006-12-12
US6489458B2 (en) 2002-12-03
EP0973928B1 (en) 2010-05-05
CA2280997A1 (en) 1998-09-17
DK0973928T3 (da) 2010-08-09
AU745049B2 (en) 2002-03-07
US20020016975A1 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
JP2002511741A (ja) 細胞のｄｎａに核酸を導入するためのｄｎａ系トランスポゾンシステム
US7160682B2 (en) Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
WO1998040510A9 (en) Dna-based transposon system for the introduction of nucleic acid into dna of a cell
JP2001523450A (ja) 細胞のｄｎａへの核酸の導入のための核酸転移ベクター
JP5726522B2 (ja) トランスポゾンシステム−スリーピングビューティーのトランスポザーゼタンパク質の機能亢進性バリアント
WO2020181193A1 (en) T:a to a:t base editing through adenosine methylation
WO2010085699A2 (en) Mammalian piggybac transposon and methods of use
JPWO2005003342A1 (ja) メチル化を利用したトランスジェニック生物を作製する方法およびシステム
US8399257B2 (en) Transposition of maize Ac/Ds elements in vertebrates
JPWO2005054463A1 (ja) レトロトランスポゾンを用いた哺乳動物のゲノム改変技術の開発
US7951927B2 (en) Reconstructed human mariner transposon capable of stable gene transfer into chromosomes in vertebrates
JP2001500729A (ja) 哺乳類及びヒトｒｅｃ２
JP7236718B2 (ja) ゲノム編集技術
US20060288437A1 (en) Zinc finger-based drug-dependent gene regulation system
JP2006262708A (ja) α−アクチンプロモーター遺伝子、発現ベクター及び遺伝子導入魚類
Borén et al. 7 Genetic Analysis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070724

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20071219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080428

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20080828

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080912